Novo Nordisk (NVO) said Monday it plans to invest 8.5 billion Danish kroner ($1.20 billion) to establish a new production facility in Odense, Denmark.
The new site will feature a 40,000-square-meter production facility and warehouse and will produce treatment for rare diseases, such as hemophilia, the Norwegian life sciences company said.
The plant will be powered in part by solar energy, the company said. Construction has already begun and is scheduled to be completed in 2027 when it will employ 400 permanent personnel, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.